BridgeBio Pharma, Inc. (BBIO) — Cost of Revenue
| Fiscal Year | Cost of Revenue | Change YoY |
|---|---|---|
| 2025 | $20.96M | +440.5% |
| 2024 | $3.88M | +58.5% |
| 2023 | $2.45M | -28.8% |
| 2022 | $3.43M | +10.3% |
| 2021 | $3.11M | — |
| Fiscal Year | Cost of Revenue | Change YoY |
|---|---|---|
| 2025 | $20.96M | +440.5% |
| 2024 | $3.88M | +58.5% |
| 2023 | $2.45M | -28.8% |
| 2022 | $3.43M | +10.3% |
| 2021 | $3.11M | — |